Trial Search Results

COVID-19 in Patients With Chronic Liver Diseases

This study seeks to determine how COVID-19 affects the clinical outcome of patients with chronic liver disease, and whether the clinical course of COVID-19 is influenced by underlying chronic liver disease.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Other: Prospective Chart Review


Inclusion Criteria:

   - Confirmed diagnosis of COVID-19

   - Personal history of either

      - Chronic hepatitis C

      - Chronic hepatitis B

      - Alcoholic liver disease

      - Non alcoholic liver disease

      - Autoimmune hepatitis, Primary biliary cholangitis, Primary sclerosing cholangitis

      - Cryptogenic cirrhosis

      - Hepatocellular carcinoma

Exclusion Criteria:

   - Non-COVID-19 patient

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305